Posted by Phillipa on September 17, 2015, at 17:42:28
In reply to FDA approves Vraylar for schizophrenia, bipolar, posted by Tomatheus on September 17, 2015, at 17:06:52
Newest | Oldest
Dr. Julie Atwood| Psychiatry/Mental Health 20 minutes ago
No drug in this class has yet to be free of serious metabolic effects, particularly in bipolar patients, so I will be very cautious with this drug until a more thorough examination is available.FlagLikeReply
Dr. T H| Psychiatry/Mental Health 1 hour ago
Interesting. Cariprazine "decreased symptoms" of schizophrenia and bipolar disorder compared to placebo, Side effects are mostly EPS, Early development of EPS is a warning sign of possible TD later on.Unless the reduction of symptoms is substantial and the drug is not too expensive, what would be the rationale to use it when we have drugs with lot less side effects?Flag1LikeReply
Dr. Charles Bensonhaver| Psychiatry/Mental Health 1 hour ago
We already have a wide spectrum of agents efficacious in Schizophrenia and Bipolar Disorder. What value added does this have? I am sure it is not cheap, so there needs to be a very good reason to prescribe it.Flag1LikeReply
Dr. Sukhjit Brar| Psychiatry/Mental Health 1 hour ago
I don't see any mention about metabolic side effects and any effect on qtc interval. The positive thing is that patients have more options to choose from.FlagLikeReply
Dr. Bob Gale| Psychiatry/Mental Health 1 hour ago
There is no such thing as a "side" effect when a chemical is added to a person (who is essentially a machine made and run by and with chemicals). There are only good "positive," adverse "bad" (either or both with variable type and intensity, and no effects. The term "side effect," created by pharma, insurance, medical providers, and their lawyers, was invented and then used to prevent/diminish lawsuits and increase patient awareness, expectation, acceptance, and fear, increase sales and allow for frequently deceptive advertising. It is inherently a dishonest term and also obfuscates the very real differences among people's type and degree of reaction to ingesting a "foreign" chemical, including the relatively unique responses as well as the 20-40% that don't respond well, but don't prevent FDA approval. Bob Gale, MD, JDFlag1LikeReply
Dr. Rangaesh Gadasalli| Internal Medicine 2 hours ago
As many serious side effects have been reported with in a short period of six weeks,that also includes death in seniors with dementia, CAUTION should be exercised by all Health care providers in prescribing this new drug. One good thing is , that we have many good drugs to treat Schizophrenia now. Olanzapine, Zipra sidone, Risperidone and Seroqul have been in the market for more than a decade and millions of patients have benefited from these Medications. what is needed is careful regular monitoring of patients for hematological issues-(leucopenia,) and weight gain is important.
poster:Phillipa
thread:1082598
URL: http://www.dr-bob.org/babble/20150901/msgs/1082600.html